REGN - Regeneron Pharmaceuticals Inc Stock Price, Fair Value and News

$723.24-18.76 (-2.53%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

REGN Price Action

Last 7 days

-7.8%

Last 30 days

12.6%

Last 90 days

27.5%

Trailing 12 Months

-3.5%

REGN RSI Chart

REGN Valuation

Market Cap

76.0B

Price/Earnings (Trailing)

16.6

Price/Sales (Trailing)

5.34

EV/EBITDA

13.31

Price/Free Cashflow

14.99

REGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

REGN Fundamentals

REGN Revenue

Revenue (TTM)

14.2B

Rev. Growth (Yr)

0.9%

Rev. Growth (Qtr)

2.14%

REGN Earnings

Earnings (TTM)

4.6B

Earnings Growth (Yr)

8.91%

Earnings Growth (Qtr)

4.92%

REGN Profitability

EBT Margin

36.11%

Return on Equity

14.79%

Return on Assets

11.4%

Free Cashflow Yield

6.67%

REGN Investor Care

Buy Backs (1Y)

2.69%

Diluted EPS (TTM)

41.82

REGN Alerts

3 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	14.1B	14.2B	14.2B	0
2024	13.1B	13.5B	13.8B	14.2B
2023	12.4B	12.7B	13.1B	13.1B
2022	16.5B	14.2B	13.7B	12.2B
2021	9.2B	12.4B	13.5B	16.1B
2020	7.0B	7.4B	7.9B	8.5B
2019	6.6B	6.5B	6.6B	6.6B
2018	6.1B	6.2B	6.4B	6.7B
2017	5.0B	5.2B	5.5B	5.9B
2016	4.4B	4.6B	4.7B	4.9B
2015	3.1B	3.4B	3.8B	4.1B
2014	2.3B	2.5B	2.6B	2.8B
2013	1.6B	1.7B	1.9B	2.1B
2012	565.4M	762.0M	1.1B	1.4B
2011	467.7M	459.7M	456.5M	445.8M
2010	0	0	0	459.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

CEO	Dr. Leonard S. Schleifer M.D., Ph.D.
WEBSITE	regeneron.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	12256

Regeneron Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Regeneron Pharmaceuticals Inc? What does REGN stand for in stocks?

REGN is the stock ticker symbol of Regeneron Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Regeneron Pharmaceuticals Inc (REGN)?

As of Wed Dec 03 2025, market cap of Regeneron Pharmaceuticals Inc is 76.01 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of REGN stock?

You can check REGN's fair value in chart for subscribers.

Is Regeneron Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether REGN is over valued or under valued. Whether Regeneron Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Regeneron Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REGN.

What is Regeneron Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, REGN's PE ratio (Price to Earnings) is 16.6 and Price to Sales (PS) ratio is 5.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Regeneron Pharmaceuticals Inc's stock?

In the past 10 years, Regeneron Pharmaceuticals Inc has provided 0.026 (multiply by 100 for percentage) rate of return.